Cellular Biomedicine Group Inc was originally incorporated in the State of Arizona on June 25, 2001. The Company is engaged in the field of biomedicine. The Company through its wholly-owned subsidiary Cellular Biomedicine Group Ltd. (BVI), is involved in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell technologies, which include, without limitations, TC-DC (tumor cell specific dendritic cells) for treatment of a broad range of cancers, haMPC (human adipose-derived mesenchymal progenitor cells) for treatment of joint disease, huMPC (human umbilical cord-derived mesenchymal progenitor cells), MNP (human embryo-derived motor neuron precursor cells) and NP (human embryo-derived motor neuronal precursor cells) for treatment of central nervous system diseases. Its biomedicine business was founded in 2009 as a newly formed specialty biomedicine company by a team of seasoned Chinese-American executives, scientists and doctors. The Company operates two reporting segments. The majority of all assets are contained in Biomedicine segment with the majority of the operations located in the People's Republic of China. The Company's Consulting segment provides services to foreign and domestic companies seeking access to the U.S. capital markets. It has built an intellectual property portfolio towards freedom of operation within its specialties in the cellular biomedicine field. Its portfolio contains patents, trade secrets, and know-how. Its technology can be grouped based on origin of progenitor or stem cells into adipose, umbilical cord, bone marrow and embryo.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.